Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib

被引：2
|
作者：
Spraggs, C. F. [1 ]
Parham, L. R. [2 ]
Song, K. [3 ]
Briley, L. P. [2 ]
Johnson, T. [1 ]
Russo, M. [3 ]
Tada, H. [3 ]
du Bois, A. [4 ]
Xu, C. -F. [1 ]
机构：
[1] GlaxoSmithKline Res & Dev Ltd, Stevenage, Herts, England
[2] PAREXEL Int, Durham, England
[3] GlaxoSmithKline Res & Dev Ltd, Philadelphia, PA USA
[4] Kliniken Essen Mitte, Essen, Germany
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷 / 07期
关键词：
CHRONIC MYELOID-LEUKEMIA; CHINESE INDIVIDUALS; CANNOT ACCOUNT; RESISTANCE;
D O I：
10.1093/annonc/mdv211
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Previous reports suggest that an inherited BIM deletion polymorphism is associated with clinical resistance to EGFR-targeted TKI therapy in EGFR-mutated NSCLC. Herein we evaluate the potential association of BIM deletion with response to TKI treatment in renal cell carcinoma, ovarian cancer, and HER2-overexpressing metastatic breast cancer.
引用
收藏
页码：1515 / 1517
页数：3
相关论文
共 22 条
  • [1] Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on NSCLC carcinoma cell lines
    Commo, Frederic
    Olaussen, Ken A.
    Tailler, Maximilien
    Lacroix, Ludovic
    Vitale, Ilio
    Raza, Syed Q.
    Richon, Catherine
    Dessen, Philippe
    Lazar, Vladimir
    Kroemer, Guido
    Soria, Jean-Charles
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S595 - S596
  • [2] Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines
    K A Olaussen
    F Commo
    M Tailler
    L Lacroix
    I Vitale
    S Q Raza
    C Richon
    P Dessen
    V Lazar
    J -C Soria
    G Kroemer
    Oncogene, 2009, 28 : 4249 - 4260
  • [3] Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines
    Olaussen, K. A.
    Commo, F.
    Tailler, M.
    Lacroix, L.
    Vitale, I.
    Raza, S. Q.
    Richon, C.
    Dessen, P.
    Lazar, V.
    Soria, J-C
    Kroemer, G.
    ONCOGENE, 2009, 28 (48) : 4249 - 4260
  • [4] The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?
    Addeo, Raffaele
    Caraglia, Michele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (02) : 139 - 142
  • [5] Association of BIM Deletion Polymorphism With Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Adenocarcinoma
    Wu, Shang-Gin
    Liu, Yi-Nan
    Yu, Chong-Jen
    Yang, Pan-Chyr
    Shih, Jin-Yuan
    JAMA ONCOLOGY, 2016, 2 (06) : 826 - 828
  • [6] A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
    King Pan Ng
    Axel M Hillmer
    Charles T H Chuah
    Wen Chun Juan
    Tun Kiat Ko
    Audrey S M Teo
    Pramila N Ariyaratne
    Naoto Takahashi
    Kenichi Sawada
    Yao Fei
    Sheila Soh
    Wah Heng Lee
    John W J Huang
    John C Allen
    Xing Yi Woo
    Niranjan Nagarajan
    Vikrant Kumar
    Anbupalam Thalamuthu
    Wan Ting Poh
    Ai Leen Ang
    Hae Tha Mya
    Gee Fung How
    Li Yi Yang
    Liang Piu Koh
    Balram Chowbay
    Chia-Tien Chang
    Veera S Nadarajan
    Wee Joo Chng
    Hein Than
    Lay Cheng Lim
    Yeow Tee Goh
    Shenli Zhang
    Dianne Poh
    Patrick Tan
    Ju-Ee Seet
    Mei-Kim Ang
    Noan-Minh Chau
    Quan-Sing Ng
    Daniel S W Tan
    Manabu Soda
    Kazutoshi Isobe
    Markus M Nöthen
    Tien Y Wong
    Atif Shahab
    Xiaoan Ruan
    Valère Cacheux-Rataboul
    Wing-Kin Sung
    Eng Huat Tan
    Yasushi Yatabe
    Hiroyuki Mano
    Nature Medicine, 2012, 18 : 521 - 528
  • [7] A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
    Ng, King Pan
    Hillmer, Axel M.
    Chuah, Charles T. H.
    Juan, Wen Chun
    Ko, Tun Kiat
    Teo, Audrey S. M.
    Ariyaratne, Pramila N.
    Takahashi, Naoto
    Sawada, Kenichi
    Fei, Yao
    Soh, Sheila
    Lee, Wah Heng
    Huang, John W. J.
    Allen, John C., Jr.
    Woo, Xing Yi
    Nagarajan, Niranjan
    Kumar, Vikrant
    Thalamuthu, Anbupalam
    Poh, Wan Ting
    Ang, Ai Leen
    Mya, Hae Tha
    How, Gee Fung
    Yang, Li Yi
    Koh, Liang Piu
    Chowbay, Balram
    Chang, Chia-Tien
    Nadarajan, Veera S.
    Chng, Wee Joo
    Than, Hein
    Lim, Lay Cheng
    Goh, Yeow Tee
    Zhang, Shenli
    Poh, Dianne
    Tan, Patrick
    Seet, Ju-Ee
    Ang, Mei-Kim
    Chau, Noan-Minh
    Ng, Quan-Sing
    Tan, Daniel S. W.
    Soda, Manabu
    Isobe, Kazutoshi
    Noethen, Markus M.
    Wong, Tien Y.
    Shahab, Atif
    Ruan, Xiaoan
    Cacheux-Rataboul, Valere
    Sung, Wing-Kin
    Tan, Eng Huat
    Yatabe, Yasushi
    Mano, Hiroyuki
    NATURE MEDICINE, 2012, 18 (04) : 521 - 528
  • [8] Pharmacokinetic (PK)-pharmacodynamic correlation, biologic and clinical effects of GW786034 (pazopanib), a VEGF tyrosine kinase inhibitor (TKI), in patients (pts) with solid tumors
    Suttle, B.
    Saini, S.
    Kathman, S.
    Arumugham, T.
    Whitehead, B.
    Nixon, A.
    Hurwitz, H.
    Dowlati, A.
    Pandite, L.
    EJC SUPPLEMENTS, 2006, 4 (12): : 27 - 27
  • [9] Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors
    Bellantoni, Andrew J.
    Wagner, Lars M.
    CANCERS, 2021, 13 (14)
  • [10] Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: An update of recent developments
    Steeghs, Neeltje
    Nortier, Johan W. R.
    Gelderblom, Hans
    ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) : 942 - 953
123